公开(公告)号：KR101346132B1

公开(公告)日：2013-12-31

申请号：KR1020130016915

申请日：2013-02-18

Applicant: 강원대학교산학협력단

Inventor： 이한수 ,  진영준 ,  변희정 ,  이문성 ,  최종선

IPC: C07K16/24 ,  C12N15/13 ,  A61K39/395 ,  A61P35/00

Abstract: The present invention relates to an anti-MIC-1 monoclonal antibody, MBM-14 inhibiting angiogenesis of MIC-1, and more specifically, to an antibody which specifically combines to MIC-1 containing a light chain variable region with amino acid sequences 1,2 and 3 on complementarity determining regions which are CDR1, CDR2 and CDR3 and heavy chain variable region with amino acid sequences 4,5 and 6 on complementarity determining regions which are CDR1, CDR2 and CDR3. The antibody of the present invention is capable of effectively suppressing angiogenesis induced by MIC-1. Therefore, growth and metastasis of tumors can be stopped, and by using the present invention, treatments can be possible not only cancer, but also diseases related to angiogenesis such as arthritis, diabetes, retina disease, arteriosclerosis and psoriasis. Such treatments can be possible since the antibody of the present invention specifically combines to MIC-1 to disturb combination between MIC-1 and a receptor. In addition, antibodies with improved treatments effects can be invented based on the information of the antibody of the present invention.

Abstract translation: 本发明涉及抗MIC-1单克隆抗体，MBM-14抑制MIC-1的血管生成，更具体地说，涉及与含有轻链可变区的MIC-1与氨基酸序列1， 2和3对互补决定区是CDR1，CDR2和CDR3，重链可变区与氨基酸序列4,5和6互补决定区是CDR1，CDR2和CDR3。 本发明的抗体能够有效抑制由MIC-1引起的血管生成。 因此，可以停止肿瘤的生长和转移，并且通过使用本发明，不仅可以进行癌症治疗，还可以进行与血管生成相关的疾病如关节炎，糖尿病，视网膜疾病，动脉硬化和牛皮癣的治疗。 这样的处理是可能的，因为本发明的抗体与MIC-1特异性结合以干扰MIC-1和受体之间的组合。 此外，可以基于本发明的抗体的信息来发明具有改善的治疗效果的抗体。